23andMe Drug Response: What You'll Actually See in a Report From Your Data

This is the practical walkthrough of what a drug response report looks like. To be clear about who does what: 23andMe gives you the raw genetic data, and Gene2Rx turns that file into the report. So when you upload your 23andMe raw data to Gene2Rx, here is what actually shows up, which medications get flagged, what the recommendations say, and how to use them with your doctor. The full report covers 110 medications on the same CPIC^[1] and FDA^[2] guidelines clinicians use, runs in minutes, and costs $5 for a starter report or $49 for the full version.

When your doctor writes a prescription, they are making an educated guess that the standard dose will work for you. For most patients it does. For a meaningful minority it does not. A drug response report tells you in advance which medications are worth closer attention, based on your genotype. You do not need a new test for this if you have 23andMe data; the relevant genetic markers are already in the raw data file you can download and hand to Gene2Rx.

Gene2Rx groups medications by your metabolizer phenotype for each relevant gene. A typical output for someone who turns out to be a CYP2C19 intermediate metabolizer: sertraline flagged with a dose-reduction note, escitalopram flagged similarly, citalopram flagged with a maximum-dose cap, omeprazole flagged with dose-frequency guidance, and clopidogrel flagged with an alternative-therapy note.^[4] Each flag links to the underlying CPIC or FDA guideline so you can see exactly what the clinical basis is. This is the Gene2Rx report, not anything 23andMe produces; 23andMe only supplies the genotype data underneath it.

Most prescribing clinicians will accept a pharmacogenetic report as useful information, especially for medications where CPIC has published dosing guidelines. Practical approach: share the report before your next prescription decision (not after a medication has already failed you), highlight the recommendations relevant to what you are discussing, and let your clinician decide how to weigh them. The report does not tell you to change any medication on its own; it gives your clinician better information to make the call.

Gene2Rx covers 110 medications across psychiatric, cardiovascular, pain, chemotherapy, transplant, and gastrointestinal classes. Many you will not be taking today, and that is the point. Your metabolizer phenotype is a lifelong fact, so the report is a reference document you will pull out years from now when a doctor prescribes something new. Someone who learns at 30 that they are a CYP2D6 poor metabolizer will use that across decades: opioids after a future surgery, beta blockers if they develop hypertension, antidepressants if they ever need them. The report never expires because your DNA does not change.

23andMe is a consumer product built for ancestry and traits, not a clinical-grade assay, and the raw data download is labeled as not for medical use. The chip reads a fixed set of positions, so it reliably covers the common pharmacogenetic variants used in most guideline recommendations. It does not detect structural variants such as gene duplications and deletions. That gap matters most for CYP2D6,^[5] where an extra gene copy can make someone an ultrarapid metabolizer and a deleted copy can leave almost no enzyme at all. For most prescribing questions the 23andMe data is a strong, low-cost starting point; for a high-stakes, one-time decision, a clinician may confirm a key result with a clinical-grade test.

Here are specific phenotype outputs you will see in your Gene2Rx report, and what each means for drug response in practice. The phenotype is read from your 23andMe genotype data; the interpretation is Gene2Rx's.

Your 23andMe data contains the genotype calls for all of these. Gene2Rx extracts them, maps them to CPIC^[1] and FDA^[2] phenotype categories, and produces the report. The underlying biology does not depend on which service interpreted the data; what Gene2Rx adds is the breadth of medication coverage, the guideline citations, and the report format.

The highest-value moments to pull up your drug response report: before starting any new prescription, before a procedure where an opioid might be prescribed (codeine and tramadol are the main pharmacogenetically sensitive ones^[5]), when a medication you have tried has not worked as expected, or when a close family member is starting treatment for a condition that runs in your family (your report applies to relatives with useful probability).

• 23andMe Pharmacogenetics: How to Get a Drug Response Report From Your Existing Data
• AncestryDNA for Drug Testing: Get Pharmacogenetics From Your Ancestry Data
• Looking for a GeneSight Alternative? Here's the Short Answer
• Looking for a Genomind Alternative? Here's What to Know
• MyHeritage Pharmacogenetics: Use Your MyHeritage DNA for a Drug Response Report
• Nebula Genomics Pharmacogenetics: How to Get a Drug Response Report From Your WGS Data

110 medications across every major drug class where CPIC or FDA has published pharmacogenetic guidance. That includes antidepressants (sertraline, escitalopram, citalopram, paroxetine, venlafaxine, amitriptyline, vortioxetine), antipsychotics (aripiprazole, brexpiprazole, clozapine), ADHD medications (atomoxetine, amphetamine), pain medications (codeine, tramadol), cardiovascular drugs (clopidogrel, warfarin, metoprolol, statins), PPIs (omeprazole, pantoprazole), chemotherapy agents (capecitabine, fluorouracil, mercaptopurine, azathioprine, tamoxifen), immunosuppressants (tacrolimus), and infectious-disease drugs (efavirenz, voriconazole).

Download the PDF from your Gene2Rx account and bring it to your appointment, or email it ahead of time. Highlight the medications relevant to your current discussion. Most pharmacogenetic-aware clinicians will read the specific recommendations and factor them in. If your doctor is not familiar with pharmacogenetics, the CPIC and FDA source citations on each recommendation help them see the evidence base.

It can narrow the field meaningfully. If you are a CYP2C19 poor metabolizer, citalopram and escitalopram are usually poor first choices because they accumulate and risk QT prolongation at higher doses. If you are a CYP2D6 poor metabolizer, paroxetine and venlafaxine may reach higher plasma levels than expected. The report does not pick an antidepressant for you, but ruling out classes where your phenotype makes standard dosing risky is often more than half the work.

Do not change anything on your own. Bring the specific findings to your prescribing clinician. For many patients, being a CYP2D6 or CYP2C19 poor metabolizer on a medication that has worked for years is informative but not urgent; you have shown empirically that you tolerate the dose. For patients who have had side effects or poor response, the finding often explains the pattern and can guide a switch to a better-fitting alternative.

Yes. 23andMe's own FDA-authorized report reads a small, fixed set of variants, is framed as wellness information, and recommends clinical confirmation before acting. Your Gene2Rx report covers 110 medications with per-phenotype recommendations from CPIC and FDA guidelines, generated from the same raw data file, which is substantially more than 23andMe's built-in feature provides.

For life. Your genetics do not change. The clinical guidelines behind the report update occasionally as research emerges, so for high-stakes prescribing it is worth re-running the report every few years to catch material changes. For most uses, the report you generate today will still be accurate in 20 years.